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INTRODUCTION: A LAWYER’S GUIDE TO
CRISPR*
JOHN M. CONLEY**
This Symposium on Legal, Ethical, and Policy Implications of
New Gene-Editing Technologies was motivated by recent scientific
developments in the field of gene editing. For years, genomic
medicine has been hailed as the future of clinical treatment. The
general premise is that doctors will use detailed information about a
particular patient’s DNA (and other “biomarkers”) to custom-tailor
diagnoses, advice, drug choices and doses, and other specifics of
treatment.1 President Obama’s highly publicized Precision Medicine
Initiative2 (now rebranded—cryptically—as the “All of Us” Research
Program)3 illustrates both the hope and the hype.
Despite this hope and hype, genomic medicine has thus far had a
limited effect on the day-to-day practice of medicine, and that effect
has been most notable in cancer treatment (for example, the use of
BRCA gene testing in treating breast cancer made famous by
Angelina Jolie).4 The limiting factors have included the facts that (1)
genes tend to influence the probability of getting a disease but rarely
“cause” a disease in a deterministic sense; (2) the relative influences
of environment, lifestyle, and epigenetic factors (changes in DNA’s

* © 2019 John M. Conley.
** William Rand Kenan, Jr. Professor, University of North Carolina School of Law.
My thanks to UNC law students Brian Champion, Zan Newkirk, and Zachary Shufro for
their excellent research assistance to me and other contributors to the Symposium.
1. See generally Alan Wong et al., Multiplexed Barcoded CRISPR-Cas9 Screening
Enabled by CombiGEM, 113 PROC. NAT’L ACAD. SCI. 2544 (2016) (providing an
overview of the ability to tailor diagnoses, drug choice, and treatment options through
CRISPR-Cas9 screening of patients).
2. Press Release, Office of the Press Sec’y, White House, Fact Sheet: President
Obama’s Precision Medicine Initiative (Jan. 30, 2015), https://obamawhitehouse.archives.gov/
the-press-office/2015/01/30/fact-sheet-president-obama-s-precision-medicine-initiative
[https://perma.cc/9U9H-8H7N].
3. See All of Us Research Program, ALL OF US, https://www.joinallofus.org/en
[https://perma.cc/3HCR-2EJJ].
4. See, e.g., Angelina Jolie, Opinion, My Medical Choice, N.Y. TIMES (May 14, 2013),
https://www.nytimes.com/2013/05/14/opinion/my-medical-choice.html [https://perma.cc/
H8DP-LS3P].
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immediate chemical environment in the body) on the ways genes are
expressed are only beginning to be understood; and (3) for the rare
cases of clear genetic-disease causation, treatment can only be
symptomatic, since we have no “cures” at the genetic level.5
In fact, the holy grail of genomic medicine has always been the
ability not just to identify dangerous gene mutations but to fix them:
to go into a patient’s cells and change a dangerous DNA sequence to
a healthy one. There have been efforts to do “gene therapy” by using
viruses and other vectors to add desired DNA into the patient’s cells.
There have been some limited successes6 but also some catastrophic
failures, most infamously the death of a teenage boy in Pennsylvania7
and cases of leukemia-like side effects in France.8 In hindsight, the
problems were probably due to insufficient knowledge about the
DNA-delivery mechanisms.9
Now a new “gene-editing” technology, called CRISPR (or
CRISPR-Cas9), may have the potential to provide a safe and effective
way to cut out mutated sequences of DNA and paste in normal
variants. As is so often the case in science, it is actually a new
application of old knowledge—in this case, about the immune systems
of bacteria. There is a long way to go before CRISPR becomes part of
patient care, but, for the first time, there seems to be a way to
leapfrog the use of potentially risky vectors to deliver DNA into a
patient’s cells. The promise and potential value of the technology is
reflected in the epic struggle underway over the foundational patent
rights, featuring MIT and the Broad Institute on one side and the
University of California-Berkeley and several European luminaries

5. Irwin Fridovich et al., Human Genetic Disease: Management of Genetic Disease,
ENCYCLOPEÆDIA BRITANNICA, https://www.britannica.com/science/human-genetic-disease/
Management-of-genetic-disease [https://perma.cc/GQ4Z-VJPS].
6. There is a rare eye disease (choroideremia), for example, where in a trial of “14
patients [who] receiv[ed] a single injection into the back of the eye of a virus containing
the missing gene” that caused their visual impairment, “there was a significant gain in
vision across the group of patients as a whole . . . which was sustained for up to five years
at the last follow up.” Gene Therapy Breakthrough in Treating Rare Form of Blindness,
NIHR OXFORD BIOMEDICAL RES. CTR. (Oct. 8, 2018), https://oxfordbrc.nihr.ac.uk/genetherapy-breakthrough-in-treating-rare-form-of-blindness/ [https://perma.cc/VM7M-GH6V].
7. Sheryl Gay Stolberg, The Biotech Death of Jesse Gelsinger, N.Y. TIMES MAG.,
Nov. 28, 1999, at 136, 137–38.
8. Andrew Pollack, F.D.A. Halts 27 Gene Therapy Trials After Illness, N.Y. TIMES
(Jan. 15, 2003), https://www.nytimes.com/2003/01/15/us/fda-halts-27-gene-therapy-trialsafter-illness.html [https://perma.cc/D96D-9J6D].
9. Id.
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on the other—a biomedical Clash of Titans.10 Meanwhile, in 2015 a
Chinese research team reported the first successful gene-editing
intervention in nonviable human embryos,11 followed last year by a
Chinese scientist’s claim to have edited the genome of twin baby
girls.12
The rapid development of CRISPR technology—in particular,
the ethically dubious Chinese activities—has spurred consternation,
debate, and governance proposals among scientists, bioethicists,
lawmakers, and regulators. The contributors to this Symposium are
all significant contributors to this emerging discourse. In this
Symposium, our contributors explain gene-editing technology and
explore its significant implications for law, ethics, regulation, and
health policy from their varied perspectives. In this Introduction, I
will give a brief, “CRISPR for Lawyers” overview of the technology
and then provide a synopsis of each of the contributions to this
Symposium.
I. HOW CRISPR WORKS
CRISPR (pronounced “crisper,” like the lettuce drawer in the
refrigerator) stands for Clustered Regularly Interspaced Short
Palindromic Repeats.13 These are short, repeating sequences in the
DNA of E. coli and other bacteria that were discovered by Japanese
researchers in the 1980s.14 DNA is made up of long, two-stranded
chains of four chemical building blocks, or bases: A,T,C, and G.15 The
specific arrangement, or sequence, of these bases determines the

10. John Conley, Clash of Titans: The Fight Over the CRISPR Gene-Editing Patent
Rights,
ROBINSON
BRADSHAW:
PRIVACY
REP.
(Oct.
8,
2018),
https://theprivacyreport.com/2018/10/08/clash-of-titans-the-fight-over-the-crispr-gene-editingpatent-rights/ [https://perma.cc/HNF4-TQMD].
11. David Cyranoski & Sara Reardon, Chinese Scientists Genetically Modify Human
Embryos, NATURE (Apr. 22, 2015), https://www.nature.com/news/chinese-scientistsgenetically-modify-human-embryos-1.17378 [https://perma.cc/N3PN-JVB4].
12. Dennis Normile, CRISPR Bombshell: Chinese Researcher Claims to Have Created
Gene-Edited Twins, SCIENCE (Nov. 26, 2018, 1:10 PM), https://www.sciencemag.org/
news/2018/11/crispr-bombshell-chinese-researcher-claims-have-created-gene-edited-twins
[https://perma.cc/HB4X-F52G].
13. Brad Plumer et al., A Simple Guide to CRISPR, One of the Biggest Science Stories
of the Decade, VOX (Dec. 27, 2018), https://www.vox.com/2018/7/23/17594864/crispr-cas9gene-editing [https://perma.cc/N6AM-MBMA].
14. Id.
15. Richard J. Roberts et al., Nucleic Acid, ENCYCLOPÆDIA BRITANNICA,
https://www.britannica.com/science/nucleic-acid#ref594016 [https://perma.cc/8KXY-WVD3].
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nature of the organism—in simplest terms, whether it’s a bacterium or
me.16
The CRISPR regions of bacteria were an enigma to the scientists
who first noticed them. Their function was unknown for about twenty
years, when food scientists using bacteria to make yogurt figured out
that they are part of the bacteria’s immune system.17 These scientists
realized that the CRISPR sequences resemble the DNA of viruses.18
In fact, the CRISPR sequences are taken from viral DNA that the
bacteria has captured during past viral invasions.19 When a new viral
attack occurs, the bacteria’s immune system compares the virus’s
genetic material to the sequences stored in CRISPR; if it detects a
match, it launches enzymes to cut up the incoming viral DNA and
repel the invasion.20
The details of this recognize-and-destroy process have proved
critical to developing CRISPR’s gene-editing potential. But first a bit
more terminology: An organism’s genome is the entirety of its DNA;
genes are those DNA sequences that function to build, or encode,
proteins.21 Genes account for only a small portion of the DNA in the
genome.22 Other portions of the genome have regulatory functions,
controlling when particular genes switch on and off, while other areas
have no known current function.23 RNA is a single-stranded cousin of
DNA that performs many functions in the cell.24
The bacterial CRISPR sequences are always accompanied by
genes that code for enzymes (a class of proteins that facilitate
chemical reactions) that can cut DNA.25 The original CRISPR
scientists called them Cas (for CRISPR-associated) genes.26 Later
research revealed that when viruses invade a bacterial cell, the
16. Id.
17. Plumer et al., supra note 13.
18. Id.
19. Id.
20. Id.
21. Help Me Understand Genetics, GENETICS HOME REFERENCE (May 14, 2019),
https://ghr.nlm.nih.gov/primer [https://perma.cc/72WD-LN52].
22. Jonathan Henninger, The 99 Percent . . . of the Human Genome, HARV. U.: SCI.
NEWS (Oct. 1, 2012), http://sitn.hms.harvard.edu/flash/2012/issue127a/ [https://perma.cc/
ECM6-4HV9].
23. Id.
24. Carl Zimmer, Breakthrough DNA Editor Born of Bacteria, QUANTA MAG. (Feb.
6, 2015), https://www.quantamagazine.org/crispr-natural-history-in-bacteria-20150206/
[https://perma.cc/3Q9J-D2CE].
25. Plumer et al., supra note 13.
26. Id.
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CRISPR regions produce RNA versions of the viral DNA sequences
that it has captured and stored.27 These RNA sequences are cradled
by the Cas enzymes and carried around the cell.28 When an RNA
sequence encounters its viral DNA counterpart, it latches on and the
Cas enzyme cuts the DNA, which stops the virus from replicating.29
Current CRISPR gene-editing technology mimics this natural
process. Researchers at the University of California-Berkeley chose a
Cas enzyme called Cas9.30 They supplied the enzymes with the RNA
counterpart of the genetic sequence they wanted to edit—the target
gene.31 The RNA finds and binds to the target DNA and the Cas9
enzymes cut it at its two ends.32 With the target gene excised, the cell
can be induced to make a new one.33 In the simplest application, the
CRISPR mechanism finds and cuts out a “defective” gene—for
example, one that causes a single-gene disease such as cystic fibrosis,
hemophilia, or sickle cell disease—and the cell replaces it with a
normal one.34 CRISPR technology can also be used to introduce a
new gene into the space.35
This image provides a simple visual representation of how
CRISPR-Cas9 is used to find and cut a target gene (the g in gRNA
stands for guide; PAM is a DNA sequence adjacent to the target
sequence that Cas9 recognizes36):

27. Id.
28. Id.
29. Id.
30. Id.
31. Id.
32. Id.
33. Id.
34. Id.
35. Zimmer, supra note 24.
36. ADDGENE, CRISPR 101: A DESKTOP RESOURCE 9, 24–25 (2d ed. 2017),
https://bit.ly/2uRYyG0 [https://perma.cc/ACU8-SLX3].
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CRISPR-Cas9

Image Credit: Marius Walter, GRNA-Cas9, WIKIMEDIA
COMMONS (Sept. 25, 2017), https://commons.wikimedia.org/
wiki/File:GRNA-Cas9.png
[https://perma.cc/9RSM-DDL8].
This image is licensed under the Creative Commons
Attribution-ShareAlike 4.0 International license. See
Attribution-ShareAlike 4.0 International License, CREATIVE
COMMONS,
https://creativecommons.org/licenses/by-sa/4.0/
legalcode [https://perma.cc/65BG-NRTQ].
CRISPR is not the first gene-editing technology. Other
approaches include Zinc-finger nucleases (“ZFN”) and transcription
activator-like effector nucleases (“TALENs”).37 ZFN, which dates to
the early 1990s, employs custom-engineered proteins that find, bind
to, and cut target DNA sequences.38 ZFN improved on prior
technology by significantly improving the accuracy of gene editing, in
particular by reducing “off-target” edits that hit the wrong DNA
sequences with unpredictable consequences.39 However, ZFN’s

37. Id. at 53.
38. Thomas Gaj, Charles A. Gersbach & Carlos F. Barbas III, ZFN, TALEN, and
CRISPR/Cas-Based Methods for Genome Editing, 31 TRENDS BIOTECHNOLOGY 397,
398–99 (2013).
39. Id. at 400–01.
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custom engineering of proteins for each new target gene makes it
slow, expensive, and inefficient.40 TALENs, which appeared in 2009,
is generally similar to ZFN but simpler and more efficient.41 CRISPR
represents a major advance over both in terms of efficiency and
accuracy.42
There is a long way to go before CRISPR gene editing becomes
part of everyday patient care, but it has the potential both to “fix” the
causes of single-gene diseases and to contribute to the prevention or
treatment of diseases that are caused by a complex interaction of
genes and environmental factors, including cancer and heart disease.43
Such uses seem—at least at first glance—to be ethically
unproblematic, though there are worries about such safety issues as
off-target edits.44 But other possible uses are already engendering
profound ethical concerns. Those uses include enhancement, or gene
editing to improve on normal human traits;45 editing human sperm or
egg cells, which raises concerns about the intergenerational protection
of those who might inherit edited genomes;46 gene editing of embryos,
the subject of the recent Chinese claims;47 gene editing of animals, for
a variety of purposes;48 and attempting to alter ecology, as in the
proposed use of CRISPR to eliminate malarial mosquitoes.49 Such
concerns are the subject of many of the Articles in this Symposium.
40. ADDGENE, supra note 36, at 8.
41. J. Boch et al., Breaking the Code of DNA Binding Specificity of TAL-Type III
Effectors, 326 SCIENCE 1509, 1509–12 (2009); Gaj et al., supra note 38, at 399.
42. ADDGENE, supra note 36, at 9.
43. See id. at 15; Mark Shwartz, Target, Delete, Repair, STAN. MED. (2018),
https://stanmed.stanford.edu/2018winter/CRISPR-for-gene-editing-is-revolutionary-but-itcomes-with-risks.html [https://perma.cc/QVZ5-ZLZZ].
44. Gaj et al., supra note 38, at 402.
45. See, e.g., Shwartz, supra note 43.
46. See, e.g., Jianhua Luo, Here’s What We Known About CRISPR Safety – And
Reports
of
‘Genome
Vandalism’,
WASH.
POST
(Sept.
3,
2018),
https://www.washingtonpost.com/national/health-science/heres-what-we-know-about-crisprsafety--and-reports-of-genome-vandalism/2018/08/31/2ed90212-9735-11e8-a679-b09212fb69c2_
story.html?noredirect=on&utm_term=.9ed673af0653 [https://perma.cc/6ZGT-LZHW].
47. See, e.g., Normile, supra note 12.
48. See, e.g., Preetika Rana & Lucy Craymer, Big Tongues and Extra Vertebrae: The
Unintended Consequences of Animal Gene Editing, WALL ST. J. (Dec. 14, 2018),
https://www.wsj.com/articles/deformities-alarm-scientists-racing-to-rewrite-animal-dna11544808779 [https://perma.cc/BYJ3-U87M]; see also THE NETH. COMM’N ON GENETIC
MODIFICATION (COGEM), CRISPR & ANIMALS: IMPLICATIONS OF GENOME EDITING
FOR POLICY AND SOCIETY 5–6 (2018).
49. See, e.g., Megan Molteni, Here’s the Plan to End Malaria with CRISPR-Edited
Mosquitos, WIRED (Sept. 24, 2018, 11:00 AM), https://www.wired.com/story/heres-theplan-to-end-malaria-with-crispr-edited-mosquitoes/ [https://perma.cc/XTE4-FU9Q]; see
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II. SUMMARY OF THE ARTICLES
The Articles in this issue are ordered generally according to
theme. The first three deal in various ways with the ethics and legality
of human gene editing. In Human Gene-Editing Research, Nancy
King’s primary concern is the creation of inheritable gene changes.
Her worries include the perpetuation of dangerous outcomes and the
use of gene editing for enhancement rather than treatment.
Expressing skepticism about global enforcement mechanisms, she
argues rather for transparency, ongoing discussion, and the
development of best practices.
Next, Vence Bonham and Lisa Smilan’s Somatic Genome Editing
in Sickle Cell Disease uses the history of sickle cell disease to explore
the issue of equitable access to gene-editing treatments. Sickle cell
disease is a prime candidate for the early application of somatic gene
editing, but, as the authors document, the history of the treatment of
people living with the disease is one of discrimination and health
inequities. They offer ethical prescriptions for policymakers in an
effort to avoid a repeat of that tragic story.
Then, in Editing Humanity, Paul Enríquez examines the legality
of human germline editing from multiple legal perspectives. He
concludes that the Food and Drug Administration has ample current
authority to regulate the practice but offers an innovative
constitutional argument against efforts to ban germline gene-editing
technologies. He proposes organizing possible uses of germline
editing along an ethical continuum and using this continuum as a
blueprint for future regulation.
A second group of Articles addresses gene editing in relation to
animals and the environment. Rebecca Walker and Matthias Eggel
focus on the ethics of using animals to model potential human
applications of CRISPR. In Replacement or Reduction of Gene-Edited
Animals in Biomedical Research, they identify the inherent ethical
tension in the trend toward reducing the number of animals used
while at the same time replacing mice and rats with more
“complex”—and thus more humanlike—species such as primates.
In Before We Make a Pig’s Ear of It, Karen Meagher and Paul
Thompson use recent nuisance suits against the North Carolina hogalso Dylan Matthews, The Bold Plan to End Malaria with a Gene Drive, VOX (Sept. 26,
2018,
5:03
PM),
https://www.vox.com/science-and-health/2018/5/31/17344406/crisprmosquito-malaria-gene-drive-editing-target-africa-regulation-gmo [https://perma.cc/HG2QRZ39].
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farming industry as a vehicle for thinking about the ethics of the gene
editing of livestock. They argue for new bioethical frameworks that
combine divergent perspectives as policymakers grapple with ethical
problems at the intersection of the environment, public health, and
the legitimate needs of agriculture.
Governing Extinction in the Era of Gene Editing, by Jonas
Monast, explores CRISPR technology as a conservation tool,
including such uses as improving the genetic diversity of endangered
species, controlling invasive species, and even reviving extinct species.
The problem is that, whereas traditional conservation methods allow
time and space for debating competing values, CRISPR-based
conservation may move too fast. Monast offers a framework based in
the Endangered Species Act to ensure that conservation uses of gene
editing undergo appropriate public policy analysis.
Three more Articles examine some of the health implications of
gene editing. Legal and Ethical Implications of CRISPR Applications
in Psychiatry, by Alexandra Foulkes and colleagues, addresses
psychiatry’s increasing focus on the genomic correlates of many
conditions. The authors identify some of the conditions that are
especially promising for gene-editing treatment, as well as the special
clinical challenges that CRISPR presents in the mental-health
context. They conclude with some thoughts about the ethical and
legal issues that are likely to arise, focusing particularly on the
vulnerability of psychiatric patients who are likely to enlist in geneediting research.
In DIY CRISPR, Christi Guerrini, Evan Spencer, and Patricia
Zettler explore the overlooked and unregulated world of “citizen
scientists” doing CRISPR research on their own, and sometimes on
themselves. The authors’ extensive interview study reveals a
surprisingly robust—and generally effective—self-regulatory regime.
But their interviews also identify emerging challenges that may
portend an increase in risky experimentation.
Then, in Gene Therapy’s Field of Dreams, Laura Hercher and
Anya Prince consider the critical question of who will pay for gene
therapy. It is expensive and, because it is individualized, it is likely to
remain so. Consequently, cost should be a fundamental concern, lest
we slip into a world of “genetic haves and have-nots,” a world in
which health inequalities are even more profound than they are now.
In our final Article, The Pick-and-Shovel Play, Jacob Sherkow
and Christopher Scott take a bioethical perspective on the role of
patents in the development of gene-editing technology. While the
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debate thus far has been largely limited to the propriety of patents on
gene-editing technologies themselves, the authors urge greater
attention to the vectors that are used for introducing gene-editing
mechanisms into the body. They contend that some commercial
players have shrouded their vector information in secrecy, raising
serious ethical and safety issues about the therapies in which those
vectors are used.

